High materiality7/10
Kymera Therapeutics initiated with an Outperform at Raymond James
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Raymond James initiated KYMR with Outperform; target price $140; current price $109.30.
- Target $140; Price $109.30; Raymond James
Key facts
- 01
Target: $140
- 02
Posted price: $109.3
- 03
Analyst firm: Raymond James
- 04
Analyst: Thomas Deal
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.